Physostigmine concentrations after oral doses.
作者信息
Gibson M, Moore T, Smith C M, Whelpton R
出版信息
Lancet. 1985 Mar 23;1(8430):695-6. doi: 10.1016/s0140-6736(85)91353-4.
PMID:2858639
Abstract
摘要
相似文献
1
Physostigmine concentrations after oral doses.口服剂量后的毒扁豆碱浓度。
Lancet. 1985 Mar 23;1(8430):695-6. doi: 10.1016/s0140-6736(85)91353-4.
2
Plasma physostigmine concentrations after oral administration.口服给药后血浆毒扁豆碱浓度。
Lancet. 1985 Jun 15;1(8442):1397-8. doi: 10.1016/s0140-6736(85)91827-6.
3
Plasma physostigmine concentrations after controlled-release oral administration.控释口服给药后血浆毒扁豆碱浓度。
Arch Neurol. 1989 Jan;46(1):13. doi: 10.1001/archneur.1989.00520370015007.
4
Sensitive analysis of plasma physostigmine levels using dual-cell electrochemistry in the redox mode.在氧化还原模式下使用双池电化学对血浆毒扁豆碱水平进行灵敏分析。
J Chromatogr. 1990 Mar 16;526(1):97-107. doi: 10.1016/s0378-4347(00)82487-1.
5
6
Pharmacokinetics of physostigmine in man following a single application of a transdermal system.单次应用透皮给药系统后毒扁豆碱在人体的药代动力学。
Br J Clin Pharmacol. 1995 Jan;39(1):59-63. doi: 10.1111/j.1365-2125.1995.tb04410.x.
7
Quantitative assay of physostigmine in human whole blood.人全血中毒扁豆碱的定量测定。
J Pharm Sci. 1977 Mar;66(3):389-91. doi: 10.1002/jps.2600660320.
8
Oral administration of heptylphysostigmine in healthy volunteers: a preliminary study.健康志愿者口服庚基毒扁豆碱的初步研究。
Methods Find Exp Clin Pharmacol. 1994 Jun;16(5):373-6.
9
Bioavailability of oral physostigmine.口服毒扁豆碱的生物利用度。
N Engl J Med. 1985 Nov 14;313(20):1293-4. doi: 10.1056/NEJM198511143132016.
10
Hypertension associated with oral administration of physostigmine in a patient with Alzheimer's disease.阿尔茨海默病患者口服毒扁豆碱后出现高血压。
Am J Psychiatry. 1986 Jul;143(7):910-2. doi: 10.1176/ajp.143.7.910.
引用本文的文献
1
Clinical pharmacokinetics of cholinesterase inhibitors.胆碱酯酶抑制剂的临床药代动力学。
Clin Pharmacokinet. 1986 May-Jun;11(3):236-49. doi: 10.2165/00003088-198611030-00005.
Zotero 插件